Petosemtamab is under clinical development by Merus and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II drugs for Vulvar Cancer have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Petosemtamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Petosemtamab (MCLA-158) is under development for the treatment of metastatic colorectal cancer and other solid tumors including cervical cancer, vaginal cancer, vulvar cancer, penile cancer, anal cancer, non-small cell lung cancer, squamous non-small cell lung cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, endometrial cancer, pancreatic cancer, salivary gland cancer, squamous esophageal cancer and head and neck squamous cell carcinoma. The therapeutic candidate is administered through intravenous route. It is a bi-specific monoclonal antibody which acts by targeting leucine rich repeat containing G protein-coupled receptor 5 (LGR5) and epidermal growth factor receptor (EGFR). The therapeutic candidate is developed based on ADCC-Biclonics technology platform.
Merus is a pharmaceutical company that discovers and develops antibody therapeutics for cancer indications. The company is investigating MCLA-128, for the treatment of metastatic breast cancer and solid tumors; ONO-4685, for the treatment of autoimmune disease. It is also evaluating MCLA-158 and MCLA-129, to treat solid tumors and MCLA-145, a T-cell agonist targeting hematological malignancy and solid tumors. Merus utilizes Multiclonics, Biclonics and Triclonics technology platform for developing antibodies to treat cancer. The company works in collaboration with Incyte Corporation, Simcere Pharmaceutical Group, Ono Pharmaceutical Co., Ltd. and Betta Pharmaceuticals Co Ltd to advance its pipeline products. Merus is headquartered in Utrecht, the Netherlands.
For a complete picture of Petosemtamab’s drug-specific PTSR and LoA scores, buy the report here.